ClinicalTrials.gg
CompletedNCT03868358Updated Apr 15, 2021

Effect of Intermittent Theta Burst Stimulation (iTBS) for Alleviating Symptoms of Schizophrenia Patients

An interventional study of transcranial magnetic stimulation in Schizophrenia, Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation, sponsored by WANG KAI. Completed at 1 site in China. Open to participants aged 18 Years to 52 Years. Per ClinicalTrials.gov, last updated 2021-04-15.

Sponsored by WANG KAI · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2017, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 52 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.

Enrollment
149th of 216
60 · median 100
Started
2017
with 14 others
No phase
110 of 252
36 open now
Registered
111th of 252
by date

Among the 252 studies in Schizophrenia with a site in China, this one is the 149th largest by enrollment of the 216 interventional ones that give a count, is one of 15 that started in 2017, is one of 110 with no phase, and was the 111th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 52 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

To investigate the treatment effect of intermittent theta-burst transcranial magnetic stimulation on symptomatic relief of schizophrenia patients, and the underlying neural mechanism by functional MRI and the resting electroencephalogram

Read the detailed description

All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after intermittent theta-burst transcranial magnetic stimulation (iTBS) treatment. Patients were randomly allocated to iTBS group and the sham group by coin toss. There are about 30 patients in each group.The decision to enroll a patient was always made prior to randomization. Patients were studied using a double-blind design. Study participants, clinical raters, and all personnel responsible for the clinical care of the patient remained masked to allocated condition and allocation parameters. Only iTBS administrators had access to the randomization list; they had minimal contact with the patients, and no role in assessing the Positive and Negative Syndrome Scale (PANSS). Each patient would be treated for continuous 14 days by iTBS.Before the iTBS treatment, PANSS and Clinical Global Impression-severity of illness (CGI-SI) at baseline were obtained by a trained investigator to assess baseline severity of their symptoms. Scale for the Assessment of Negative Symptoms (SANS) and Scale for Assessment of Positive Symptoms (SAPS) were respectively supplemented to evaluate the severity of symptoms in different dimensions,.The patients had receiving a battery measure of neuropsychological tests (standardized tests to investigate their cognitive problems, anxiety and depressive symptoms in daily life), magnetic resonance imaging scan in multimodalities, electroencephalography (EEG), event-related potentials during stop signal test and Iowa-gambling test record. Other behavioral tests including intertemporal decision,spatial n-back test record.

After the last treatment, the Positive and Negative Syndrome Scale were obtained, as well as the Global Index of Safety to assess adverse events of the treatment. Patients were instructed to focus their answers on the past 14 days. The patients had also receiving a battery measure of neuropsychological tests, magnetic resonance imaging scan in multimodalities, and EEG record.Clinical Global Impression-global improvement (CGI-GI), Clinical Global Impression-efficacy index (CGI-EI) were evaluated at the end of treatment.

40-60 days after the last treatment, participants were interviewed to obtain the Positive and Negative Syndrome Scale,SAPS,SANS and HAMA,HAMD. They were instructed to focus their answers on the past week. Additionally, they were also asked to assess the battery of neuropsychological tests, and have magnetic resonance imaging scan in multimodalities, and EEG record. Afterwards, they were unblinded by the study coordinator.

03

Conditions studied

  • Schizophrenia
  • Functional Magnetic Resonance Imaging
  • Transcranial Magnetic Stimulation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 52 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients met diagnostic criteria for schizophrenia or schizoaffective disorder using the Structural Clinical Interview for Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-IV (SCID, Version 2.0).
  • Patients remain their psychotropic medication at steady dosages for at least 4 weeks prior to study entry and for the duration of the trial.
  • Verbal intelligence quotient > 85 as measured by using a Chinese version of the National Adult Reading Test.

Exclusion criteria

Exclusion Criteria:

  • History of significant head trauma or neurological disorders
  • Alcohol or drug abuse Focal brain lesions on T1- or T2-weighted fluid-attenuated inversion-recovery magnetic resonance images
  • a prior history of a seizure not induced by drug withdrawal,first degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease, such as thyroid disease, significant unstable medical condition, recent aggression or other forms of behavioral dyscontrol
  • left-handedness, pregnancy
  • estimated intelligence quotient\<80
  • current alcohol or drug abuse
  • inability to provide .
  • Hamilton Anxiety Rating Scale or the Hamilton Depression Rating Scale score > 14
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Real Stimulation

    Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks

    Device: transcranial magnetic stimulation

  • Placebo comparator
    Sham Stimulation

    Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks

    Device: transcranial magnetic stimulation

Interventions

  • Devicetranscranial magnetic stimulation

    The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks. Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks

06

What researchers measure

Primary outcomes

  1. Positive And Negative Syndrome Scale(PANSS)

    The improvment in PANSS scores will constitute the major research outcome measure used to assess response to rTMS,reflecting the symptom improvment in patients

    Time frame: Baseline and 2 weeks post-treatment,and follow-up

Secondary outcomes

  1. Scale for the Assessment of Positive Symptoms (SAPS)

    The improvment in SAPS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' positive symptoms

    Time frame: Baseline and 2 weeks post-treatment and follow-up

  2. Scale for the Assessment of Negative Symptoms (SANS)

    The improvment in SANS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' negative symptoms

    Time frame: Baseline and 2 weeks post-treatment and follow-up

  3. Functional connectivity change of transcranial magnetic stimulation(iTBS and sham)

    Functional MRI measures: the functional connectivity between stimulated target and the whole brain areas

    Time frame: Baseline and 2 weeks post-treatment

  4. EEG change of transcranial magnetic stimulation(iTBS and sham)

    EEG measures: brain areas wave change of stimulation(iTBS and sham)

    Time frame: Baseline and 2 weeks post-treatment

  5. Intertemporal decision test

    Intertemporal decision test is associated with the function of left dorsolateral prefrontal cortex

    Time frame: Baseline and 2 weeks post-treatment

  6. Spatial n-back test

    Spatial n-back test will reflect the prefrontal function

    Time frame: Baseline and 2 weeks post-treatment

  7. Multidimensional Empathy Test

    Multidimensional empathy Test is associated with the function of left dorsolateral prefrontal cortex

    Time frame: Baseline and 2 weeks post-treatment

07

Study locations

1 site
  • Anhui Medical University
    Hefei, Anhui 230032, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2020, 37 months.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 37 months is above that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2019
First posted
Mar 11, 2019
StartActual
May 21, 2017
Primary completionActual
Jul 9, 2020
CompletionActual
Mar 30, 2021
Last update
Apr 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03868358
Lead sponsor
WANG KAI
Responsible party
WANG KAI (Dept of Neurology & Medical Psychology, Director, Cognitive Neuropsychology Lab Anhui Medical University, PRC, Anhui Medical University) — Sponsor-investigator
First posted
Mar 11, 2019
Start date
May 21, 2017
Primary completion
Jul 9, 2020
Completion
Mar 30, 2021
Last update
Apr 15, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion